- Home
- AIHS vs IBIO Comparison
AIHS vs IBIO Comparison
Compare AIHS & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIHS
- IBIO
- Stock Information
- Founded
- AIHS 2014
- IBIO 2008
- Country
- AIHS China
- IBIO United States
- Employees
- AIHS N/A
- IBIO N/A
- Industry
- AIHS Finance: Consumer Services
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AIHS Finance
- IBIO Health Care
- Exchange
- AIHS Nasdaq
- IBIO Nasdaq
- Market Cap
- AIHS 9.9M
- IBIO 9.3M
- IPO Year
- AIHS 2018
- IBIO N/A
- Fundamental
- Price
- AIHS $0.94
- IBIO $0.73
- Analyst Decision
- AIHS
- IBIO Strong Buy
- Analyst Count
- AIHS 0
- IBIO 3
- Target Price
- AIHS N/A
- IBIO $4.87
- AVG Volume (30 Days)
- AIHS 22.7K
- IBIO 2.3M
- Earning Date
- AIHS 06-26-2025
- IBIO 05-02-2025
- Dividend Yield
- AIHS N/A
- IBIO N/A
- EPS Growth
- AIHS N/A
- IBIO N/A
- EPS
- AIHS N/A
- IBIO N/A
- Revenue
- AIHS $5,878,700.00
- IBIO $375,000.00
- Revenue This Year
- AIHS N/A
- IBIO $36.00
- Revenue Next Year
- AIHS N/A
- IBIO N/A
- P/E Ratio
- AIHS N/A
- IBIO N/A
- Revenue Growth
- AIHS 12.21
- IBIO 650.00
- 52 Week Low
- AIHS $0.77
- IBIO $0.64
- 52 Week High
- AIHS $1.45
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- AIHS 52.38
- IBIO 24.07
- Support Level
- AIHS $0.89
- IBIO $0.75
- Resistance Level
- AIHS $1.06
- IBIO $0.82
- Average True Range (ATR)
- AIHS 0.05
- IBIO 0.14
- MACD
- AIHS 0.00
- IBIO 0.10
- Stochastic Oscillator
- AIHS 42.86
- IBIO 3.04
About AIHS Senmiao Technology Limited
Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.